Figure 2

HOXB13 disrupts β-catenin/TCF-mediated signals. (A) Real-time RT–PCR was performed to show baseline levels of HOXB13 in established colorectal tumour cell lines. Normal rectum and LNCaP prostate cancer cells were used as references. (B) Cells were transiently transfected with 100 ng of pIRES-TCF4RE-Luc, 20 ng of pCMV-β-gal, and 100 ng of pFLAG-HOXB13 with or without 10 nM R1881. pFLAG-CMV was used as a counterpart of pFLAG-HOXB13. ^*P<0.05. (C) CV-1 cells were transfected with either pGL-TATA-luc or pBV-myc-luc and pIRES-HOXB13. ^*P=0.02.